Meta Information
ID:tirzepatide
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/antidiabetic-medications
Target name:
Insulin or Insulin Secretagogues (e.g., Sulfonylureas)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Tirzepatide lowers blood glucose and has an additive effect with other glucose-lowering medications, significantly increasing the risk of severe hypoglycemia.
Actionable advice:
A dose reduction of concomitant insulin or sulfonylurea may be required; monitor blood glucose frequently.
Target id:
/class/glp-1-receptor-agonists
Target name:
Other GLP-1 Receptor Agonists (e.g., Semaglutide)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Combining Tirzepatide with other GLP-1 receptor agonists is duplicative therapy, offers no additional benefit, and significantly increases the risk of gastrointestinal side effects.
Actionable advice:
Avoid using Tirzepatide in combination with any other GLP-1 receptor agonist.
Target id:
/condition/medullary-thyroid-carcinoma-history
Target name:
Personal or Family History of Medullary Thyroid Carcinoma (MTC)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
In animal studies, Tirzepatide caused thyroid C-cell tumors. Due to this potential risk, it is contraindicated in individuals with a personal or family history of MTC.
Actionable advice:
Avoid completely if you or a family member has a history of Medullary Thyroid Carcinoma.
Target id:
/condition/men-2-syndrome
Target name:
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Patients with MEN 2 are at high risk for Medullary Thyroid Carcinoma (MTC), making Tirzepatide contraindicated due to the potential risk of thyroid C-cell tumors.
Actionable advice:
Avoid completely if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Target id:
/class/estrogens
Target name:
Oral Hormonal Contraceptives
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Tirzepatide delays gastric emptying, which can reduce the absorption and effectiveness of oral hormonal contraceptives, increasing the risk of unintended pregnancy.
Actionable advice:
Use a non-oral contraceptive or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
Target id:
/procedure/surgery-anesthesia
Target name:
Surgery with General Anesthesia
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
168
Hours after target:
null
Description:
The delay in gastric emptying caused by Tirzepatide increases the risk of vomiting and aspiration of stomach contents during anesthesia.
Actionable advice:
Discontinue Tirzepatide at least 1 week prior to elective surgeries requiring general anesthesia.
Target id:
/condition/history-of-pancreatitis
Target name:
History of Pancreatitis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
GLP-1 receptor agonists have been associated with acute pancreatitis; it is unknown if the risk is higher in those with a prior history, so caution is warranted.
Actionable advice:
Use with caution and discontinue immediately if you develop severe abdominal pain suggestive of pancreatitis.
Target id:
/condition/severe-gi-disease
Target name:
Severe Gastrointestinal Disease (e.g., Gastroparesis)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Tirzepatide slows gastric emptying and has not been studied in patients with severe GI disease; it is likely to worsen symptoms.
Actionable advice:
Avoid use if you have severe gastroparesis or other significant gastrointestinal motility disorders.
Target id:
/intervention/resistance-training
Target name:
Resistance Training
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Weight loss induced by Tirzepatide involves both fat and lean mass. Resistance training is essential to stimulate muscle protein synthesis and preserve muscle mass and strength.
Actionable advice:
Incorporate a consistent resistance training program (at least 2-3 times per week) to mitigate muscle loss.
Target id:
/intervention/protein
Target name:
Adequate Protein Intake
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
The appetite suppression and caloric deficit from Tirzepatide can lead to significant muscle loss if dietary protein is insufficient to meet the body's needs.
Actionable advice:
Consume adequate daily protein (e.g., 1.2-1.6 g/kg of ideal body weight) to support muscle preservation.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Based on animal reproduction studies, there may be risks to the fetus from exposure to Tirzepatide during pregnancy. It is not recommended for use.
Actionable advice:
Discontinue use at least 2 months before a planned pregnancy and avoid completely during pregnancy.
Target id:
/class/oral-medications-general
Target name:
All Oral Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Tirzepatide delays gastric emptying, which can slow the absorption rate and potentially reduce the total amount absorbed of any co-administered oral medication.
Actionable advice:
Be aware that the onset of action for other oral medications may be delayed; monitor their effects closely.
Target id:
/class/narrow-therapeutic-index-drugs
Target name:
Narrow Therapeutic Index Drugs (e.g., Warfarin, Digoxin)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Delayed gastric emptying can alter the absorption profile of oral drugs with a narrow therapeutic index, potentially leading to sub-therapeutic or toxic levels.
Actionable advice:
Monitor drug levels and clinical effect (e.g., INR for warfarin) closely when starting or adjusting Tirzepatide.
Target id:
/condition/diabetic-retinopathy
Target name:
Diabetic Retinopathy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
In patients with a history of diabetic retinopathy, rapid improvements in glycemic control have been associated with a temporary worsening of the condition.
Actionable advice:
Monitor for any changes in vision or progression of diabetic retinopathy after starting treatment.
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Gastrointestinal side effects like vomiting or diarrhea can cause dehydration, which may lead to acute kidney injury or worsen underlying kidney disease.
Actionable advice:
Maintain adequate hydration and monitor renal function, especially if experiencing severe GI side effects.
Target id:
/intervention/alcohol
Target name:
Alcohol
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Alcohol can independently lower blood sugar, increasing the risk of hypoglycemia when combined with Tirzepatide. It may also irritate the stomach and increase pancreatitis risk.
Actionable advice:
Limit alcohol consumption and monitor blood glucose levels carefully if you choose to drink.
Target id:
/class/glucose-lowering-supplements
Target name:
Glucose-Lowering Supplements (e.g., Berberine)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Supplements known to lower blood sugar (such as berberine, cinnamon, or alpha-lipoic acid) can have an additive effect with Tirzepatide, increasing hypoglycemia risk.
Actionable advice:
Use caution and monitor blood glucose closely when combining with supplements that affect blood sugar.
Target id:
/class/dpp4-inhibitors
Target name:
DPP-4 Inhibitors (e.g., Sitagliptin)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The combination has not been studied and is not recommended, as both drug classes work by increasing incretin hormone levels, leading to overlapping mechanisms.
Actionable advice:
Avoid using Tirzepatide in combination with a DPP-4 inhibitor.
Target id:
/dietary/water
Target name:
Adequate Water/Fluid Intake
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Common gastrointestinal side effects like nausea, vomiting, or diarrhea can increase the risk of dehydration, which can lead to acute kidney injury.
Actionable advice:
Ensure consistent and adequate fluid intake throughout the day to maintain proper hydration.
Target id:
/biomarker/dexa-scan
Target name:
DEXA Scan for Body Composition
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Periodic DEXA scans provide crucial data on changes in fat mass, lean mass, and bone density, enabling adjustments to diet and exercise to optimize health outcomes.
Actionable advice:
Obtain a baseline DEXA scan before starting and monitor body composition every 3-6 months during treatment.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is unknown whether Tirzepatide is present in human milk or its effects on a breastfed infant. A decision should be made to discontinue breastfeeding or the drug.
Actionable advice:
Discuss the risks and benefits with your doctor to decide whether to use this medication while breastfeeding.
Target id:
/dietary/high-fat-meal
Target name:
Large, High-Fat Meals
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Because Tirzepatide slows stomach emptying, large or high-fat meals can remain in the stomach longer, exacerbating common side effects like nausea, bloating, and indigestion.
Actionable advice:
Favor smaller, more frequent, lower-fat meals to minimize gastrointestinal discomfort.
Target id:
/intervention/acetaminophen
Target name:
Acetaminophen (Paracetamol)
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Tirzepatide's delay of gastric emptying slows the absorption of acetaminophen, which can delay its onset of action for pain or fever relief.
Actionable advice:
Be aware that the time to pain relief from oral acetaminophen may be longer than usual.